This phase starts after discontinuation of TKI therapy, and is characterized by continued
remission with undetectable-or stable low detectable-disease by the most sensitive method …

Fifty consecutive patients with blastic chronic myelogenous leukemia were evaluated
clinically, morphologically, biochemically, and therapeutically. Forty‐five patients had a …

The characteristic course of chronic niyeloid leukaemia (CML) includes a relatively long
phase where, after non-intensive treatment, the patients remain in a clinical and …

Although chronic myelocytic leukemia (CML) represents only 15% of all cases of leukemia,
its maximal incidence occurs in the third to sixth decades of life such that individuals are …

Blast crisis terminates the life of the majority (approximately 80%) of patients with CML. The
time of its onset appears to be a random phenomenon, varying from a probable coincidence …

A proportion of patients receiving allogeneic bone marrow transplants (BMT) for chronic
myeloid leukaemia (CML) in first chronic phase relapse; most of these relapses show …

BACKGROUND Therapeutic options in Philadelphia chromosome‐positive chronic
myelogenous leukemia (Ph‐positive CML) in chronic phase include allogeneic stem cell …

Cytogenetic and enzymatic studies have shown that chronic myeloid leukemia (CML)
represents the clonal proliferation of a pluripotent stem cell. The Philadelphia chromosome …

We analyzed factors having an impact on response to treatment and survival in 78
consecutive patients with chronic myeloid leukemia (CML) in blastic transformation (BT) …

In addition to the best possible overall survival, discontinuation of the tyrosine kinase-
inhibitor (TKI) treatment [treatment free remission (TFR)] without observing a recurrence of …